This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal

Loxo Oncology (LOXO) toppled Tuesday after agreeing to codevelop two cancer therapies with drug firm Bayer (BAYRY) in a deal that could be worth up to $1.55 billion in total payments for Loxo.

XAutoplay: On | OffThe two drugs focus on what's called tropomyosin receptor kinase, or TRK, inhibition. Evidence suggests the NTRK genes, which encode for the TRKs, can become abnormally fused to other genes, prompting growth signals that can lead to cancer.

Loxo's drug, larotrectinib, targets these...

What feeling does this article give you?

#hashtags to follow:

Loxo Oncology [+]    LOXO [+]    Bayer [+]    BAYRY [+]    XAutoplay [+]    TRK [+]    NTRK [+]    TRKs [+]   

More #news: